Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 877-881

  Zasowski, Evan ^a   Bland, Christopher M ^b   Tam, Vincent H ^c   Lodise, Thomas P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b EISENHOWER ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

Antibiotic therapy; Monte carlo simulations; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFEPIME; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HOSPITAL PATIENT; HUMAN; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; PROTEIN BINDING; SENSITIVITY ANALYSIS; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MONTE CARLO METHOD; TIME;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; KIDNEY; MONTE CARLO METHOD; TIME FACTORS;

EID: 84928184134     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku435     Document Type: Article

References (21)

1. Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics:optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011; 27: 1-18.
2. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics:insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26: 1320-32.
3. Cheatham SC, Shea KM, Healy DP et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011; 37: 46-50.
4. Crandon JL, Bulik CC, Kuti JL et al. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-6.
5. Tam VH, McKinnon PS, Akins RL et al. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003; 47: 1853-61.
6. Nicasio AM, Ariano RE, Zelenitsky SA et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53: 1476-81.
7. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide:Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles, CA, USA: Biomedical Simulations Resource, 2009.
8. Kessler RE, Bies M, Buck RE et al. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum b-lactam antibiotics. Antimicrob Agents Chemother 1985; 27: 207-16.
9. Patel N, Scheetz MH, Drusano GL et al. Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. J Antimicrob Chemother 2010; 65: 2285-90.
10. Patel N, Scheetz MH, Drusano GL et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillintazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010; 54: 460-5.
11. CraigWA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
13. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
14. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
15. Lodise TP Jr, Patel N, Kwa A et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510-5.
16. Cefepime For Injection Package Insert. Revised: 06/2012. Lake Forest, IL, USA: Hospira, Inc.
17. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 3.1, 2013. http://www.eucast.org.
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
19. Lamoth F, Buclin T, Pascual A et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010; 54: 4360-7.
20. Butterfield JM, Lodise TP, Beegle S et al. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother 2014; 69: 176-9.
21. Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.